Rafael Holdings, Inc. (RFL) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$1.36

From 52W high−65.87%

Volume76199.00

Market cap$67.08M

P/E (TTM)—

P/S (TTM)68.4x

Div yield—

Key dataOct 19, 2026

Open

$1.36

From 52W high

−65.87%

Volume

76199.00

Market cap

$67.08M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.4x

P/E (TTM)

—

RSI (14)

32.3

MomentumView details →

1D Return

−7.19%

YTD Return

+13.56%

SummaryUpdated Apr 1, 2026

Rafael Holdings, Inc. (NASDAQ:RFL) is a dual-purpose investment company founded in 2017 and publicly traded since March 2018. The company operates as a holding entity with interests in two distinct sectors: pharmaceutical development through its subsidiary Rafael Pharmaceuticals, and commercial real estate assets. Headquartered in Newark, New Jersey, Rafael Holdings represents an unusual corporate structure that combines biotech investment with real estate operations, creating a diversified investment vehicle for shareholders seeking exposure to both high-risk pharmaceutical development and stable real estate income.

Ask drillr about Rafael Holdings, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−1.4x

EV/Sales

43.5x

P/S (TTM)

68.4x

P/B (TTM)

0.9x

ProfitabilityView details →

Gross Margin

84.39%

Net Margin

−3321.73%

EBITDA Margin

−3162.86%

ROE (TTM)

−43.18%

ROA (TTM)

−35.39%

Asset Turnover

0.01x

GrowthView details →

Revenue YoY

+33.88%

EPS YoY

+27.39%

FCF YoY

—

Revenue CAGR 3Y

+30.78%

EPS CAGR 3Y

+28.28%

EBITDA YoY

−24.23%

MomentumView details →

1D Return

−7.19%

YTD Return

+13.56%

1Y Return

−3.60%

RSI (14)

32.3

vs 50D SMA

−31.56%

vs 200D SMA

−20.38%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

3.16x

Quick Ratio

3.14x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.15

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

980000.00

Net Income (TTM)

−32.55M

Op. CF (TTM)

−31.98M

Next earningsOct 28, 2026 →

Latest newsMore news →

Rafael Holdings announced topline results from the pivotal Phase 3 TransportNPC study of Trappsol Cyclo in Niemann-Pick Disease Type C, reporting that the drug missed statistical significance on the primary endpoint but showed a directionally favorable treatment effect.20d ago

Similar companies

Altisource Portfolio Solutions S.A.ASPS Richly Field China Development Limited00313.HK Beijing Capital Jiaye Property Services Co., Ltd.02210.HK E-House (China) Enterprise Holdings Limited02048.HK Wing Lee Property Investments Limited00864.HK Winfull Group Holdings Limited00183.HK Find similar companies →

Latest newsMore news →

Rafael Holdings, Inc. reported preliminary Q3 2026 results, disclosing clinical trial data including an overall survival hazard ratio of 0.154 in the INPDR group and 0.057 in the expanded group.20d ago Rafael Holdings announced topline results from the pivotal Phase 3 TransportNPC study of Trappsol Cyclo in Niemann-Pick Disease Type C, reporting that the drug missed statistical significance on the primary endpoint but showed a directionally favorable treatment effect.20d ago Rafael Chairman Yuval Steinitz announces plans to expand the company's presence in the U.S., Germany, and India, including production and R&D facilities.92d ago